<DOC>
	<DOCNO>NCT00004029</DOCNO>
	<brief_summary>Phase I trial study effectiveness vaccine therapy treat patient metastatic prostate cancer . Vaccines may make body build immune response kill tumor cell .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess toxicity associate repeated vaccination recombinant vaccinia virus express prostate-specific antigen ( rV-PSA ) patient metastatic adenocarcinoma prostate . II . Determine optimal dose rV-PSA give monthly interval base cellular hormonal immunity . III . Determine whether vaccination rV-PSA associate anti-tumor activity . IV . Determine whether granulocyte-macrophage colony-stimulating factor ( GM-CSF ) effect cellular humoral immunity different rV-PSA , whether addition GM-CSF enhance antitumor effect compare rV-PSA alone . OUTLINE : This open label , dose escalation study . Patients cohorts 3-6 receive 3 vaccination rV-PSA 4-week interval ( day 1 , 29 , 57 , 85 ) absence disease progression unacceptable toxicity . Response assessment perform eight week . Patients discontinue therapy prior eight week consider unevaluable response . If dose limit toxicity observe 2 6 patient enter dose level , patient enter level MTD define precede dose level . Ten additional patient treat MTD receive granulocyte-macrophage colony-stimulating factor ( GM-CSF ) administer subcutaneously day -1 day 2 cycle . Patients HLA-A2 positive , receive 3 rV-PSA vaccination without unacceptable toxicity , study least 30 day due disease progression may continue treatment rV-PSA high dose level addition GM-CSF . Patients follow monthly 6 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven adenocarcinoma prostate evidence metastatic disease base following : Lymph node positive PSA least 10 ng/mL Bone scan positive PSA least 10 ng/mL PSA least 2 ng/mL rise follow radical prostatectomy PSA least 10 ng/mL follow radiotherapy No symptomatic metastatic disease ( bony pain ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 0 1 WBC great 2,000/mm3 Platelet count great 100,000/mm3 Bilirubin less 2.0 mg/dL AST le 4 time normal Creatinine le 2.0 mg/dL Must type HLAA2 Prior vaccinia ( smallpox ) exposure require At least normal delayed type hypersensitivity mumps Candida At least normal CD4 : CD8 ratio ( great 1 ) At least normal lymphocyte proliferation test ( Con A ) At least normal immunoglobulin level No evidence alter immune responsiveness autoimmune syndrome ( e.g. , scleroderma , systemic lupus erythematosus ) No HIV antibody No prior splenectomy No known allergy egg No active extensive skin disorder ( e.g , psoriasis , burn , impetigo , disseminate zoster ) No serious intercurrent illness No active infection unless clear least 3 day since antibiotic therapy No close contact 2 week vaccination follow people : Children le 3 year old Pregnant woman Individuals eczema skin condition list Immunosuppressed individual PRIOR CONCURRENT THERAPY : No concurrent biologic therapy No prior chemotherapy metastatic disease No prior hormone therapy metastatic disease Neoadjuvant hormone therapy prior prostatectomy radiotherapy allow No concurrent steroid hormonal medication Prior radiotherapy allow Prior surgery allow</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>